Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Gains from Investment Securities (2020 - 2024)

Historic Gains from Investment Securities for Lyell Immunopharma (LYEL) over the last 5 years, with Q1 2024 value amounting to $13.0 million.

  • Lyell Immunopharma's Gains from Investment Securities rose 3001.0% to $13.0 million in Q1 2024 from the same period last year, while for Dec 2024 it was $13.0 million, marking a year-over-year increase of 60.36%. This contributed to the annual value of $13.0 million for FY2024, which is 60.36% up from last year.
  • According to the latest figures from Q1 2024, Lyell Immunopharma's Gains from Investment Securities is $13.0 million, which was up 3001.0% from $2.9 million recorded in Q2 2023.
  • Over the past 5 years, Lyell Immunopharma's Gains from Investment Securities peaked at $43.6 million during Q3 2021, and registered a low of -$28000.0 during Q1 2022.
  • Over the past 5 years, Lyell Immunopharma's median Gains from Investment Securities value was $8.5 million (recorded in 2020), while the average stood at $16.0 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Gains from Investment Securities tumbled by 16511.63% in 2022, and later skyrocketed by 3581428.57% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Gains from Investment Securities (Quarter) stood at $7.0 million in 2020, then soared by 417.75% to $36.2 million in 2021, then plummeted by 86.21% to $5.0 million in 2022, then plummeted by 41.54% to $2.9 million in 2023, then surged by 344.78% to $13.0 million in 2024.
  • Its last three reported values are $13.0 million in Q1 2024, $2.9 million for Q2 2023, and $10.0 million during Q1 2023.